Di(tert-butyl)-5-formyl-2-pyrimidinyl-imidodicarboxylate | 416852-41-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Di(tert-butyl)-5-formyl-2-pyrimidinyl-imidodicarboxylate
• 英文别名: tert-butyl N-(5-formylpyrimidin-2-yl)-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamate
• CAS: 416852-41-0
• 化学式: C₁₅H₂₁N₃O₅
• 分子量: 323.349
• InChiKey: CZWZMZXTHMADID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  98.7
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Di(tert-butyl)-5-formyl-2-pyrimidinyl-imidodicarboxylate 在 oxone||potassium monopersulfate triple salt 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 5.0h， 生成 tert-butyl N-[5-(4-methylpiperazine-1-carbonyl)pyrimidin-2-yl]-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamate
  参考文献：
  名称：

  TW2018/29406

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氯嘧啶-5-甲醛 在 4-二甲氨基吡啶 、 ammonium hydroxide 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 14.0h， 生成 Di(tert-butyl)-5-formyl-2-pyrimidinyl-imidodicarboxylate
  参考文献：
  名称：

  TW2018/29406

  摘要：

  公开号：

文献信息

• [EN] INDOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS<br/>[FR] DERIVES D'INDOLE UTILISES EN TANT QU'ANTAGONISTES H3 D'HISTAMINE
  申请人：SCHERING CORP

  公开号：WO2004000831A1

  公开（公告）日：2003-12-31

  Disclosed are novel compounds of the formula I wherein M1 is CH or N and M2 is C(R3) or N; R1 is optionally substituted indolyl or an aza derivative thereof; R2 is optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I in combination with a H1 receptor antagonist.

  揭示了式I的新化合物，其中M1为CH或N，M2为C(R3)或N；R1为可选择地取代的吲哚基或其氮杂衍生物；R2为可选择地取代的芳基或杂环芳基；其余变量如规范中所定义。还揭示了包括式I化合物的药物组合物。还揭示了使用式I化合物治疗各种疾病或症状的方法，例如过敏、过敏引起的气道反应和充血（例如，鼻塞）等。还揭示了使用式I化合物与H1受体拮抗剂结合治疗各种疾病或症状的方法，例如过敏、过敏引起的气道反应和充血（例如，鼻塞）等。
• WO2008/108957
  申请人：——

  公开号：——

  公开（公告）日：——
• NOVEL NON-IMIDAZOLE COMPOUNDS
  申请人：Aslanian Robert G.

  公开号：US20080119487A1

  公开（公告）日：2008-05-22

  Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H 1 receptor antagonist.
• PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN
  申请人：Aslanian Robert G.

  公开号：US20100093692A1

  公开（公告）日：2010-04-15

  The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient.
• US7300941B2
  申请人：——

  公开号：US7300941B2

  公开（公告）日：2007-11-27